Welcome to our dedicated page for Skinvisible SEC filings (Ticker: SKVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Skinvisible's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Skinvisible's regulatory disclosures and financial reporting.
Skinvisible, Inc. reported another small-scale quarter for the three months ended March 31, 2026, with revenue of $5,000, unchanged from a year earlier. Operating expenses fell modestly to $130,938, helping trim the net loss to $267,184 from $281,005 in 2025.
The balance sheet remains highly strained. Cash was only $1,798, while total liabilities were $10,649,384 against total assets of $119,419, resulting in a stockholders’ deficit of $10,529,965. Management discloses that these conditions, including cumulative losses of $41,277,360, “raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing.”
The company continues to rely on licensing its Invisicare® technology, including agreements with Quoin Pharmaceuticals and Ovation Science, and highlights multiple regulatory designations and ongoing trials around Quoin’s QRX003 candidate as potential future royalty drivers, though no new revenue from these programs was recorded this quarter.
Skinvisible, Inc. reports full-year 2025 results showing minimal revenue and continued financial strain. Revenue was $20,000, unchanged from 2024, with no cost of revenues, but operating expenses of $516,315 and a net loss of $1,064,034.
The company ended 2025 with cash of $2,620, a working capital deficit of $4,990,414, and an accumulated deficit of $41,010,176, leading auditors and management to highlight substantial doubt about its ability to continue as a going concern. Skinvisible continues to rely on licensing its Invisicare delivery technology, including its key Quoin Pharmaceuticals license for QRX003 in Netherton Syndrome, which has received multiple regulatory designations and is progressing toward a potential Phase 3 program.
Skinvisible, Inc. (SKVI) filed its Q3 2025 report, showing minimal revenue alongside ongoing losses and liquidity pressure. Revenue was $5,000 for the quarter and $15,000 year‑to‑date, unchanged year over year. The company posted a net loss of $250,245 for the quarter and $805,677 for the nine months.
Cash was $645 at September 30, 2025, against total current liabilities of $4,765,644 and total liabilities of $10,138,047, resulting in a working capital deficit of $4,737,175. Accrued interest payable was $3,212,969. Management states these conditions raise substantial doubt about continuing as a going concern. Basic loss per share was $0.05 for the quarter.
Shares outstanding were 5,403,843 as of November 13, 2025. The filing notes 82,346,405 additional shares issuable in connection with convertible notes as of September 30, 2025. Internal controls were deemed not effective due to material weaknesses. Operating expenses declined year over year, and the company highlights licensing progress with Quoin and Ovation as potential future revenue drivers.